Anti-human epidermal growth factor receptor-2 (HER2) immunization can be elicited by vaccination with DNA encoding the extraor intra-cellular domain (ECD or ICD) of HER2, naked or encapsulated in viral vectors. HER2-peptides derived from ECD or ICD of HER2, and HER2-pulsed dendritic cells (DCs) or engineered DCs expressing HER2, respectively. We performed a computerbased literature search which...

• A Zirconium labeled drug was visualized in tumors by Imaging Mass Spectrometry. Time of Flight Secondary Ion Spectrometry (ToF-SIMS) used parallel with immunohistochemistry. ToF-SIMS is a quick and sensitive technique to image zirconium labelled biologics. high-precision complement immunoPET using the same established radiotracers. The human epidermal growth factor receptor 2 (HER2) specific ...


 CADTH recommends that Lynparza be reimbursed by public drug plans for the adjuvant treatment of adult patients with deleterious or suspected germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated neoadjuvant chemotherapy if certain conditions are met.
 should only covered in a confirmed type inheri...

Recent advances in the understanding of molecular underpinnings metastatic breast cancer have led to identification novel therapeutic targets. The latest update NCCN Guidelines for Breast Cancer reflects a rapidly evolving treatment landscape, highlighting growing importance combination therapies and personalized medicine managing estrogen-receptor (ER)–positive, HER2-positive, triple-negative ...

Elevated expression of fatty acid synthase (FASN) and human epidermal growth factor receptor-2 (HER2) are observed in human osteosarcoma (OS). The aim in this study is to investigate a possible connection between FASN expression and the activity of HER2. The immunohistochemistry staining was conducted on 24 OS specimens from patients, which revealed a significant positive correlation between FA...

AIMS AND BACKGROUND Basal-like breast cancer is a distinct group of tumors with heterogeneous behavior, and not all have a poor prognosis. The present study analyzed the prevalence and prognosis of early basal-like breast cancer. METHODS AND STUDY DESIGN A total of 112 patients with stage I and II breast cancer were retrospectively analyzed using immunohistochemical stains for estrogen recept...

BACKGROUND Adjuvant therapy comprising the HER2 receptor antagonist trastuzumab is associated with a significant improvement in disease-free and overall survival as compared to chemotherapy alone in localized HER2-positive breast cancer (BC). However, a subset of HER2-positive tumors seems to respond less favorably to trastuzumab. Various mechanisms have been proposed for trastuzumab resistance...

Abstract The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes hence are druggable by targeted interventions. Here, we design an anti-HER2 biparatopic tetravalent IgG fusion with a multimodal mechan...

PURPOSE The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications. MATERIALS AND METHODS We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone ...

BACKGROUND The expressions of estrogen receptor (ER) and cell surface receptor, Tyrosine Kinase Human Epidermal Growth Factor Receptor 2 (HER 2), have emerged as the most important molecular biomarkers determining the breast cancer prognosis. In this study, interactions between ER and HER2 were assessed to determine if they modulate tumor characteristics. MATERIALS AND METHODS Tissue samples ...